Hemostemix Inc. (CVE:HEM – Get Free Report) hit a new 52-week low during trading on Monday . The company traded as low as C$0.04 and last traded at C$0.04, with a volume of 28000 shares changing hands. The stock had previously closed at C$0.04.
Hemostemix Stock Performance
The firm has a market cap of C$3.59 million, a PE ratio of -1.00 and a beta of 0.55. The company has a 50-day simple moving average of C$0.06 and a 200 day simple moving average of C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Featured Stories
- Five stocks we like better than Hemostemix
- How to Use Stock Screeners to Find Stocks
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Generac Powers Ahead on the Electrification Mega-Trend
- How to Invest in Biotech Stocks
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.